Stay updated with breaking news from Webcast Only. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile…
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 ...
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company…
08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for ...
SAN DIEGO and TORONTO, Oct. 18, 2022 -- Aptose Biosciences Inc. , a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic... | October 18, 2022